Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Mishra, Sasmita ^a   Lavelle, Bianca J ^a   Desrosiers, Joe ^b   Ardito, Matt T ^c   Terry, Frances ^c   Martin, William D ^c   De Groot, Anne S ^b,c   Gregory, Stephen H ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c EpiVax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HLA A2 ANTIGEN; HLA DRB1 ANTIGEN; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BIOSYNTHESIS; DENDRITIC CELL; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PROCEDURES; SPLEEN; TRANSGENIC MOUSE; VACCINATION;

ANIMALS; ANTIGENS, CD11C; DENDRITIC CELLS; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS C; HLA-A2 ANTIGEN; HLA-DRB1 CHAINS; HUMANS; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; PROGRAMMED CELL DEATH 1 RECEPTOR; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 84905862543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104606     Document Type: Article

References (40)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. (Pubitemid 41196755)
2. Centers for Disease Control and Prevention (2008) Surveillance for acute viral hepatitis - United States, 2006. Surveillance summaries. Morbidity and Mortality Weekly Report 57: 1-24.
3. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, et al. (2012) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61: 1-32.
4. El Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36: S74-S83.
5. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V (2011) Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 45: e17-e24.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444.
7. Lange CM, Jacobson IM, Rice CM, Zeuzem S (2013) Emerging therapies for the treatment of hepatitis C. EMBO Mol Med.
8. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 85: 3173-3188.
9. Yu CI, Chiang BL (2010) A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010: 548280.
10. Halliday J, Klenerman P, Barnes E (2011) Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10: 659-672.
11. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252. (Pubitemid 28155090)
12. Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, et al. (2010) A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 53: 599-607.
13. Li S, Roberts S, Plebanski M, Gouillou M, Spelman T, et al. (2012) Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals. PLoS ONE 7: e39368.
14. Mishra S, P.T.Losikoff A.A.Self, F.Terry M.T.Ardito, et al. (2014) Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells. Vaccine (in press).
15. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, et al. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160: 3363-3373. (Pubitemid 28164729)
16. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212. (Pubitemid 30099525)
17. De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, et al. (2005) HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 23: 2136-2148. (Pubitemid 40341440)
18. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, et al. (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19: 4652-4660. (Pubitemid 32800747)
19. Peng S, Trimble C, He L, Tsai YC, Lin CT, et al. (2006) Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther 13: 67-77. (Pubitemid 41823853)
20. Pajot A, Michel ML, Fazilleau N, Pancre V, Auriault C, et al. (2004) A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 34: 3060-3069. (Pubitemid 39549385)
21. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, et al. (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184: 1953-1962. (Pubitemid 26404485)
22. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, et al. (2000) Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 60: 3239-3246. (Pubitemid 30407923)
23. Gregory SH, Sagnimeni AJ, Zurowski NB, Thomson AW (2001) Flt3 ligand pretreatment promotes protective immunity to Listeria monocytogenes. Cytokine 13: 202-208. (Pubitemid 32575450)
24. Kuzushita N, Gregory SH, Monti NA, Carlson R, Gehring S, et al. (2006) Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology 130: 453-464. (Pubitemid 43202043)
25. Wintermeyer P, Cheng CW, Gehring S, Hoffman BL, Holub M, et al. (2009) Invariant natural killer T cells suppress the neutrophil inflammatory response in a mouse model of cholestatic liver damage. Gastroenterology 136: 1048-1059.
26. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD (2012) New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 156: 279-290.
27. Sallberg MM, Frelin L, Deipolder H, et al. (2009) A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark.
28. Barnes E, Folgori A, Capone S, Swadling L, Aston S, et al. (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra1.
29. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, et al. (2011) A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141: 890-899.
30. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, et al. (2012) Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56: 2082-2093.
31. Neveu B, Debeaupuis E, Echasserieau K, Moullac-Vaidye B, Gassin M, et al. (2008) Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 48: 713-722.
32. Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, et al. (2011) Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat 18: 549-561.
33. Par G, Szereday L, Berki T, Palinkas L, Halasz M, et al. (2013) Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin. PLoS ONE 8: e67770.
34. Perrella A, Sbreglia C, Atripaldi L, Esposito C, D'Antonio A, et al. (2010) Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scand J Gastroenterol 45: 250-255.
35. +IFN-γ regulatory T cells in chronic hepatitis C infection. Immunol Cell Biol 85: 197-204.
36. + regulatory T cells in hepatitis C virus infection. J Virol 82: 5043-5053.
37. + regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog 5: e1000707.
38. Humrich J, Jenne L (2003) Viral vectors for dendritic cell-based immunotherapy. Curr Top Microbiol Immunol 276: 241-259. (Pubitemid 36538355)
39. Boonstra A, van der Laan LJ, Vanwolleghem T, Janssen HL (2009) Experimental models for hepatitis C viral infection. Hepatology 50: 1646-1655.
40. Le DT, Dubenksy TW Jr, Brockstedt DG (2012) Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol 39: 311-322.